Sepsis-associated Acute Kidney Injury by Chancharoenthana, Wiwat et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Sepsis-associated Acute Kidney Injury
Wiwat Chancharoenthana,
Asada Leelahavanichkul and Somchai Eiam-Ong
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69612
Abstract
Sepsis is a life-threatening condition caused by a dysregulated immune response to 
infection. Interestingly, sepsis mortality increases with acute kidney injury (AKI) 
and patients with AKI worsen with sepsis. It is interesting to note that most of 
the clinical trials on sepsis treatment that derived from the results of  translational 
researches are a failure. This is, in part, because of the complexity of human  sepsis 
in comparison with animal models. Another reason for the failure-translation 
might be the improper matching of the animal models to the individual patient. 
It is  possible that the main mechanism of sepsis induction in each patient with the  
variety causes of sepsis might be different. Indeed, immune response to sepsis depends 
on genetic background, route of immune activation, and organisms. Thus, sepsis 
treatment classified by “mechanistic approach” to individual patient might be more 
proper than the classification with “sepsis severity”. Specific treatment of sepsis in  
individual patient according to the specific immune response characteristic might be 
a more proper translational strategy. Indeed, the understanding in immune response 
pattern of sepsis and sepsis pathophysiology is necessary for “sepsis mechanistic 
approach”. Then, we conclude most of the topics and our hypothesis regarding 
SA-AKI in this review.
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1. Introduction
Sepsis is a condition with life-threatening organ dysfunction caused by a dysregulated host 
response to systemic infection [1]. Sepsis is the leading cause of acute kidney injury (AKI) in 
critically ill patients especially in the intensive care unit (ICU). The morbidity and mortality 
of patients with sepsis-associated AKI (SA-AKI) is still high despite an advance in supportive 
care [2, 3]. Therefore, a well understanding of SA-AKI is essential not only for nephrologists 
but also for all physicians to enhance awareness and proper initiation of managements. In 
this chapter, we discuss several topics in SA-AKI, including the potential new therapeutic 
managements.
2. Definition and classification
Because SA-AKI definition follows the definition of AKI, in general, the understanding in AKI 
definition is necessary. Despite the heterogeneity in AKI definition with more than 35 equiva-
lent terms within the last few decades [4], RIFLE (Risk, Injury, Failure, Loss of kidney function, 
End-stage kidney disease) and AKIN (Acute Kidney Injury Network)  classification systems, 
published in 2004 and 2007, respectively, are widely accepted [5]. RIFLE  classification  stratifies 
AKI according to AKI severity as determined by serum creatinine (SCr) or  glomerular filtra-
tion rate (GFR) and urine output (UO) into three categories; Risk (R), Injury (I), and Failure 
(F). In addition, RIFLE criteria also categorize advanced AKI into other two categories based 
on the duration of AKI, kidney function loss (L, persistent AKI > 4 weeks), and end-stage 
kidney disease (E, AKI > 3 months) [5]. In RIFLE classification, worsening of SCr must be 
over a 7-day period and persists for at least 24 h. In case of unknown data on previous SCr 
level, a baseline GFR between 75 and 100 ml/min/1.73 m2 is assumed, and the modification 
of diet in renal disease (MDRD) equation is recommended for an estimation of baseline renal 
function. However, the poor prediction of clinical outcomes from renal function derived by 
MDRD equation is demonstrated [6]. Therefore, RIFLE and AKIN classifications are modified 
[7]. In modified AKIN classification, the diagnostic accuracy is improved by precluding either 
SCr or GFR which discards the requirement of baseline SCr for AKI classification. Despite 
the improved diagnostic sensitivity of AKIN in comparison with RIFLE classification, AKI 
outcomes are not in consideration of AKIN system [8]. And AKIN does not synergize with 
RIFLE criteria in predicting in-hospital mortality of patients with critical illness. Recently, 
the kidney disease improving global outcomes (KDIGO) work group merges the RIFLE and 
AKIN classifications in order to establish one AKI classification [9]. KDIGO system defines 
AKI as an increase in SCr ≥0.3 mg/dL within 48 h or an increase in SCr to ≥1.5 times of baseline 
SCr or a urine volume of <0.5 mL/kg/h for 6 h. Baseline SCr is the known or presumed value 
that has occurred within the previous 7 days. In addition, AKI staging of KDIGO  follows 
the AKIN classification with a simplification. KDIGO system shows some advantages over 
the RIFLE and AKIN classifications in AKI identification and AKI-outcomes prediction. 
Moreover, KDIGO introduces a new term of “acute kidney disease, AKD” which means the 
slower increase in SCr or GFR, >7 days but <3 months. This is because renal injury in some 
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conditions progresses slowly and does not match with AKI definition where significant renal 
function declines within 7 days after the insults.
Regarding SA-AKI classification, Pereira et al. [10] demonstrate that SA-AKI with all of these 
three classifications—RIFLE, AKIN, and KDIGO—shows similar prediction ability (assessed 
by the area under the receiver operating characteristic (AUROC) curve) for in-hospital 
 mortality (RIFLE 0.652, p < 0.001; AKIN 0.686, p < 0.001; KDIGO 0.658, p < 0.001). However, 
the study shows that RIFLE and KDIGO classifications identify AKI more than AKIN criteria. 
Thus, SA-AKI is AKI induced or enhanced by sepsis which could be classified with any of 
these three classification systems. It is also interesting to note that SA-AKI is another entity 
that should be separated from nephrotoxic and ischemic causes of AKI. In fact, inflammatory 
responses in SA-AKI seem to be more prominent than ischemic and nephrotoxic AKI [11].
3. Epidemiology
A longitudinal, 10 years, cohort with more than 20 ICUs and almost 90,000 patients 
 demonstrates the increased incidence of AKI by 2.8% per year [12]. In parallel, the incidence of 
sepsis and septic shock is on the rise. In the United States, the retrospective data from 22 years 
of hospital records reveal 8.7% annual increase in diagnosis of sepsis [13]. Sepsis is the most 
common  contributing factor for AKI. The incidence of SA-AKI is 10–45% based on etiology 
and  population [14, 15]. In surgical condition, the incidence may be as high as 60–70% [16], 
especially in the ICU setting (>50%) [3]. The severity of SA-AKI also depends on the underlying 
diseases as well as causes of sepsis [17].
Populations with a high risk of SA-AKI are elderly patients, female gender, and medical 
comorbidities, including diabetes mellitus, chronic kidney disease (CKD), congestive heart 
failure, advanced liver disease, and malignancy [18, 19]. In addition, the source of infection 
and side effect of treatment also contribute as risk factors of SA-AKI. As such, intra-abdominal 
infection, urological sepsis, infective endocarditis, and blood stream infection are  conditions 
that are susceptible to SA-AKI.
4. Immune responses in sepsis
Sepsis immune responses are very complex and possibly different among diverse etiologies. The 
progression of sepsis definition is parallel to the current understanding of sepsis pathophysiology 
in each period (Figure 1).
Indeed, the importance of hyperinflammation as a major component of sepsis is  gradually 
altered by the progression in the understanding of sepsis-induced hypoinflammatory responses. 
The updated definition of sepsis focuses on organ dysfunction, host responses, and infection as 
an etiology [1]. This is due to the recognition that sepsis in the individual patient is different 
due to host factors (underlying disease, genetic susceptibility, duration of infection, and 
organ involvement) and organism factors (virulence and antibiotic susceptibility). Hence, the 
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major mechanisms responsible for sepsis and the proper therapeutic strategies to encounter 
sepsis for each patient might be different. Indeed, several responsible molecular pathways of 
sepsis-induced hyperinflammatory response have been demonstrated (e.g., Toll-like receptor 
4, Toll-like receptor 9, HMGB1, NF-κB, etc.) mostly in animal models with very rapid clinical 
 progression [20]. These sepsis models enlighten us that the harness of innate immune responses 
in several processes with adequate organism control attenuates sepsis severity [21–29]. However, 
the control of innate immune-induced hyperinflammation results in only 50% survival. This 
demonstrates that other mechanisms might also contribute to the severity of sepsis. Indeed, 
the clinical observation from patients with sepsis demonstrates immunosuppression in sepsis 
as determined by (i) high susceptibility to secondary infection, (ii) defect in delayed-type 
hypersensitivity responses, and (iii) reactivation of dormant virus (e.g., herpes group) [30]. 
From these clinical observations, immunosuppressive phase of sepsis seems to occur at the 
late phase. However, Hotchkiss et al. nicely demonstrate the importance of sepsis-induced 
immune suppression and conclude that moribund stage of patients with sepsis could occur 
shortly after the onset of sepsis (either hyperimmune or hyporesponsive phase) [30].
As such, the rapid immune exhaustion after sepsis has been demonstrated in mice with the 
defect of immune inhibition (Fc gamma receptor IIb-deficient mice) [31]. These mice lack the 
inhibitory signaling with prominent immune responses to infection. The  preconditioning 
with endotoxin induces immune exhaustion and blunt responses of subsequent  infection. In 
 translational aspect, this is an example of the rapid immune-suppressive phase that occurs 
shortly after the onset of sepsis due to the preconditioning in the susceptible host. Moreover, 
bacterial sepsis also enhances the susceptibility to secondary fungal infection [32]. Interestingly, 
Candida albicans intravenous injection alone and with sepsis causes candidemia after injection at 
7 days and 6 h, respectively. Sepsis induces candidemia approximately 1 week faster than non-
sepsis control group. This model is also demonstrated that  immunosuppression after sepsis 
could be very rapid, and the host factors are important for the direction of immune responses.
In animal model, sepsis in the pre-conditioning models, pre-existing AKI or CKD or 
lupus manifestation, demonstrates the more severe hyperimmune responses as shown by 
the  prominent cytokine storms [23, 26, 31, 33]. Then, the host factor is very important for 
inducing rapid progression due to hyper- or hypoimmune responses in sepsis. While several 
Figure 1. Summary of sepsis definition or main mechanisms in each period.
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 therapeutic strategies from animal studies are available mostly for controlling hyperimmune 
 responsiveness, the clinical study in sepsis categorizes patients according to the severity of sepsis 
but not by the characteristic of immune response. Therefore, it is not surprising that nearly all 
of the clinical studies fail and the difference between animal models versus patients is blamed 
for the translational failure. The mechanistic-oriented approach with patient characterization 
by molecular biomarkers, but not simply with sepsis severity, should be more  appropriate. 
Biomarkers for differentiating the direction of sepsis immune response are urgently needed. The 
anti-inflammatory treatment should be appropriate for patients in hyperimmune response phase 
and vice versa for immunosuppression phage. Moreover, hyper- and hypoimmune response in 
sepsis is dynamic and the monitoring biomarkers are necessary.
In addition, the molecular-oriented treatment is also an interesting topic in sepsis. For  example, 
anti-HMGB1 should be beneficial in sepsis condition with high HMGB1, and  anti-TLR-4 should be 
appropriate for patients with increased TLR-4 expression on immune cells. Due to the  possibility 
of heterogeneity pathways of sepsis immune responses, the tailor-made or individualized therapy 
might be the most suitable management of sepsis. However, the understanding in sepsis immune 
responses is still incomplete. Then, the current sepsis definition depending on sepsis-induced 
 end-organ damage regardless of mechanistic responses is still fragmentary. More studies are 
needed to reach “sepsis mechanistic approach” in the future.
5. Pathophysiology of SA-AKI
Currently, the pathophysiology of SA-AKI is not completely known. Probably renal biopsy 
is rarely performed in SA-AKI. Hence, the basic knowledge of SA-AKI is based upon animal 
models which might be relevant only to a specific condition of SA-AKI in human [34]. For an 
example, AKI from cecal ligation and puncture model might be relevant to intra-abdominal 
sepsis but less appropriate representative of pneumonia-induced AKI. The interpretation 
and results translation from bench to bedside should be properly matched between models 
and sepsis conditions in patients. Hence, the experiments on the larger animals are performed 
but, unfortunately, the models might not represent all aspects of patient conditions. With the 
data gathering from patients and animal studies, the pathophysiology of SA-AKI is, at least 
in part, through overt inflammatory process-induced renal injury, tubular tight junction (TJ) 
injury, cell cycle arrest, cellular adaptation/apoptosis, and so on [35]. Perhaps, an alteration in 
microvascular oxygen transport during sepsis might be the major pathophysiology of SA-AKI. 
Here, we summarized the mechanisms of SA-AKI mentioned in the literatures (Figure 2).
5.1. Microscopic hemodynamic disturbances
The renal microcirculation is an important delivery system of blood and oxygen to kidney 
 tissue. Decreased glomerular perfusion pressure in sepsis is due to microdynamic disturbance 
with approximately normal renal blood flow (RBF) [36]. However, reduced RBF in sepsis 
could be found only in some patients with the failure of cardiac output. In fact, sepsis induces 
 hyper-dynamic cardiac responses with relatively high cardiac output. Although RBF is 
Sepsis-associated Acute Kidney Injury
http://dx.doi.org/10.5772/intechopen.69612
67
maintained or increased in sepsis, glomerular capillary hydrostatic pressure is insufficient to 
permit effective filtration because of efferent-afferent arteriolar imbalance function. Reduced 
GFR in persistent AKI is a result of several mechanisms including inappropriate activation of 
tubuloglomerular feedback (TG feedback) [37], tubular back-leak [38], tubular stasis/obstruction, 
nephrosarca, and altered glomerular permeability.
Normally, TG feedback is controlled by the concentration of chloride delivery to the  distal 
nephron for the induction of afferent arteriole vasoconstriction. Its role is important to 
limit the hyperfiltration in case of high glomerular perfusion pressure. In SA-AKI, TG 
Figure 2. Immune responses in sepsis. Due to renal microcirculation dysfunction (glomerular and tubular capillary), 
sepsis induces chemotaxis of inflammatory cells and proinflammatory responses leading to endothelial injury (a). 
Vascular permeability increases due to the downregulation of endothelial nitric oxide synthase (eNOS) activity and 
induction of inducible nitric oxide synthase (iNOS) (b). In parallel, inflammatory responses increase tissue factor and 
induce the coagulation system as demonstrated by microvascular thrombosis (c). In addition, inflammatory responses 
induce tubular cell injury, activate cell cycle arrest at G1 phase and cell apoptosis (d). The insufficient cell energy induces 
the abnormality in fusion/fission mechanisms of mitochondria resulting in mitochondrial injury (e). The toxic cell 
environment induced predominant mitochondria fission and dysfunction mitochondria (gray circle). The successful or 
failure of mitophagy activates cell regeneration or cell apoptosis, respectively (e, lower part).
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feedback is inappropriate due to high chloride presentation at distal nephron because of 
decreased chloride reabsorption at the proximal renal tubule. This results in overt afferent 
arteriole  vasoconstriction. Marked arteriole vasoconstriction in combination with systemic 
hypotension causes profound decline in GFR [37].
Tubular cell tight junction disturbance (tubular back-leak) is in the leak-back of non-selective 
ultrafiltration and ions from renal luminal site into basolateral portion. In SA-AKI, TJ is one 
of the target actions of endotoxin. Eadon et al. demonstrates direct structural damage of LPS 
at TJ. The injury of TJ, as determined by the injury at zonula occludens-1 (ZO-1) and claudins, 
is too severe to explain with LPS-induced-hemodynamic disturbance alone [38]. The tubular 
back-leak from TJ damage reduces UO by (i) reduced urine volume due to the leaking back 
of urine into circulation, (ii) increasing intra-renal pressure (renal intracapsular pressure or 
nephrosarca) [39], and (iii) cell debris-induced tubular lumen obstruction, tubular TJ damage, 
and abnormal TG feedback mechanisms. The reduction of GFR in SA-AKI also associates 
with altered glomerular permeability due to inflammation and endotoxins-induced direct 
glomerular endothelium damage [40, 41]. Nevertheless, the exact mechanisms of glomerular 
endothelium injury in human remain unknown.
Additionally, an alteration of renal microcirculation might be a physiologic mechanism 
that aims to limit oxygen and nutrition of organisms. Melican et al. [42] demonstrated, in 
a  urosepsis model, that renal ischemia facilitates bacterial isolation and defends against 
 organisms in sepsis. The suppression of intravascular coagulation by heparin causes fatal 
urosepsis despite improved microvascular architectures.
5.2. Renal endothelial cells injury
Renal endothelial cells and its function play a central role in microcirculatory dysfunction during 
sepsis. Sepsis-induced systemic inflammatory cytokines activate endothelium cells and initiate 
the inflammatory process [41]. Moreover, sepsis induces hypercoagulable state in vessels at both 
micro- and macroscopic levels. In animal SA-AKI model, Drake et al.  demonstrates an increased 
expression of tissue factor by glomerular endothelial cells in Escherichia coli sepsis [43]. The 
hypercoagulable state in SA-AKI also contributes to localized ischemia and hypoxia in the related 
intravascular thrombosis area, even though GFR is preserved [42].
Endothelial nitric oxide (NO) synthase (eNOS) induces NO which inhibits platelet aggregation 
and leukocyte activation. During sepsis, there is depletion of eNOS and activation of inducible 
NO synthase (iNOS). While eNOS has been shown to attenuate tissue ischemia, iNOS released 
from activated leukocytes and vascular smooth muscle cells causes vascular dysfunction [44, 
45]. Langenberg et al. has recently demonstrated that NOS isoforms increase significantly in 
SA-AKI, particularly in renal cortex more than in medulla [46]. This may potentially lead to 
medullary ischemia due to intrarenal shunting.
5.3. Mitochondrial cell dysfunction, autophagy, and apoptosis
Mitochondria are organelles found in every cell and are very prominent in cells of energetic 
organs including kidney. They are known as the powerhouses of cells. Renal mitochondria are 
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most densely concentrated due to the high and constant demand for adenosine triphosphate. 
Indeed, lack of cell energy and mitochondrial injury is demonstrated in several organs in 
sepsis [47]. Normally, mitochondrial dynamics is described as characteristics of “fission”and 
“fusion.”The mitochondrial fission, a cleavage of the defective parts of a mitochondrion, 
may be important for the maintenance of healthy organelles and necessary for mitochondria 
 distribution to daughter cells during cell division. On the other hand, mitochondrial fusion 
is the multiple steps fusion between adjacent mitochondria to improve their functions. Both 
mitochondrial fission and fusion facilitate inter-mitochondria exchanges of metabolites and 
substrates to maintain the optimal functions that are essential to cell viability [48].
Autophagy is a cellular process by which cytoplasmic organelles are sequestered and  delivered 
to lysosomes for the proper degradation. Therefore, it plays a crucial role in intracellular 
nutrient turnover, cell differentiation, cellular homeostasis, and viability [49]. But the 
 overactivity of autophagy, however, may cause cell injury or death. In mouse models 
of SA-AKI, autophagy is rapidly induced and plays important roles in renoprotection 
[50]. Because mitochondria are prokaryote inhabited inside eukaryotic cell in symbiosis 
relationship, the breakdown of mitochondria will release several prokaryotic molecules that 
are capable of inflammatory activation as other pathogen-associated molecular  patterns 
(PAMPs). Hence, the autophagy on mitochondria, as referred to mitophagy, protects 
unnecessary inflammatory responses and recycles nutrients from the injured mitochondria. 
In the same line with apoptosis, autophagy is the process that requires enough cell energy. 
In the condition with the excess injured-mitochondria for autophagy, some mitochondria 
rupture and mitochondrial cytochrome C further activate cell apoptosis. As such, if there 
are too many apoptotic bodies to clear by phagocytic cells, apoptotic cells will progress into 
 secondary necrosis where the rupture of its membrane induces prominent  inflammation. 
Hence, mitophagy is also postulated to be another cytoprotective process to control  cellular 
metabolism through the balance in number of mitochondria. Mitophagy is linked to  mitochondrial 
dynamics—fission and fusion—through the surveillance and clearance  mechanisms [51].
Taken together, it is conceivable that during the early phase of SA-AKI, mitophagy is increased to 
control and clear the damaged mitochondria. However, as sepsis progress, the autophagy may 
be overwhelmed by injured mitochondria, and/or the autophagic processes are disrupted, 
leads to the abnormal cell functions. Therefore, well homeostasis of intracellular mitochondria 
to restore healthy mitochondrial mass may be essential for renoprotection and the recovery of 
renal function in SA-AKI.
5.4. Cell cycle arrest
Cell cycle arrest is a protective mechanism to avoid entering the cell cycle during injury [52], 
thereby temporarily arresting cell cycle at G
1
 stage for reducing cell damage. In cecal ligation 
and puncture septic model and folic acid-induced AKI, cyclosporine A, a known cell cycle 
arrest inducer attenuates AKI [53, 54].
In human, Kashani and colleagues propose biomarkers of cell cycle as an early biomarker of 
AKI [55]; tissue inhibitor of metalloproteinases-2 (TIMP-2), a natural inhibitor of the group of 
matrix metalloproteinase, and insulin-like growth factor-binding protein 7 (IGFBP7). IGFBP7 
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regulates the availability of insulin-like growth factor and stimulates cell adhesion. In 
addition, both TIMP-2 and IGFBP7 are responsible for several molecular pathways, 
including oxidative stress, detoxification, and inflammatory responses. Therefore, they 
represent the early stage of any stresses that affect kidney. After tubular cells injury, IGFBP7 
directly increases the expression of p21 and p53. Simultaneously, TIMP2 enhances p27 
 expression through an autocrine and paracrine manners. All of these p-proteins block the 
functions of the  cyclin-dependent protein kinase complexes (CyclD-CDK4 and CyclE-CDK2) 
during the cell-cycle promotion process. G1 cell-cycle arrest occurs momentarily for avoiding 
cell division during the injury, and this alarm could send to adjacent cells as paracrine effect. 
This mechanism needs further exploration. More recently, a new interesting hypothesis 
 mentioned that all of the injuries are the results of the cell maladaptation to an insufficient 
energy condition [56]. More studies are needed to support this interesting hypothesis.
In the real clinical situations, multiple mechanisms in combination might be responsible for 
the individual patient. Therefore, a mechanistic approach to patients with SA-AKI needs 
the integration and understanding of these mechanisms. The biomarkers for detecting these 
events might be helpful for sepsis mechanistic approach in the future.
6. Clinical approach to SA-AKI
Clinical presentation of SA-AKI is completely uncertain especially in the early phase of  sepsis. 
SA-AKI may develop simultaneously with sepsis or follow by sepsis. Therefore, physicians 
must be alert of SA-AKI when encountering with sepsis patients and vice versa—during 
evaluation of patients with AKI. In clinical practice, the individual baseline characteristics of 
patients are very useful for the proper SA-AKI management. Signs and symptoms of sepsis 
in  individual patients depend upon individual susceptibilities and are usually masked by the 
organ involvement. As mentioned earlier, the SA-AKI diagnosis depends on SCr (absolute 
increase of SCr concentration of 0.3 mg/dL over 48 h or a relative change in SCr concentration of 
1.5- to 1.9-fold to baseline over 7 days) or UO (less than 0.5 mL/kg/h for 6 h). SCr  measurement, 
however, is insensitive indicator of AKI due to the time dependence accumulation. In mice 
with bilateral nephrectomy, SCr increases from baseline as late as 12–18 h after surgery [33]. 
According to SCr half-life (t
½
), increments in SCr concentration lag the decrements in GFR by 
an hour. In addition, sepsis leads to the reduction in muscular production of creatinine from 
inflammatory process. And diuretic administration in AKI for promoting the non-oliguric 
phase results in the unreliable UO criteria. Thus, other biomarkers in addition to SCr and 
UO are required. Urine analysis and urine biochemistry indices may be useful as adjunctive 
biomarkers to support or differentiate SA-AKI. The presence of urine granular cast and renal 
epithelial cells is not only for the differentiation between pre-renal AKI and ATN but also for 
SA-AKI versus non-septic AKI [57]. Urinary sediment examination remains a classic, cost-
effectiveness, and worthwhile method for the differentiation of AKI etiologies. By contrast, 
urine chemistry indices including urine sodium (U
Na
), fractional excretion of sodium (FE
Na
), 
and fractional excretion of urea (FE
urea
) are beneficial for the differentiation of pre-renal AKI 
from acute tubular necrosis (ATN) but unfortunately unable to differentiate between SA-AKI 
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versus non-septic AKI. However, Vanmassenhove et al. [58] demonstrates that low FE
Na
 and 
low FE
urea
 are predictive of transient AKI and oliguria is predictive for impending AKI in early 
sepsis. Although some studies demonstrate the benefit of urine chemistry indices in SA-AKI, 
there is still no established urine chemistry test to differentiate SA-AKI from non-septic AKI.
As such, the quest for novel biomarkers as an earlier assessment tool for detecting SA-AKI 
is crucial. Such biomarkers are categorized into two groups: (i) the determination of renal 
functions and (ii) the detection of renal cell injury. Some lists of candidate new biomarker of 
SA-AKI are cystatin C (Cys-C), neutrophil gelatinase-associated lipocalin (NGAL),  kidney 
injury molecule-1 (KIM-1), interleukin-18 (IL-18), liver-type fatty acid-binding (L-FABP), 
soluble-triggering receptor expressed on myeloid cells-1 (sTREM-1), and activating 
 transcriptional factor 3 (ATF-3). The sensitivity and specificity of these biomarkers vary 
depending on the timing of measurement and clinical samples. Generally, blood (serum) 
 biomarkers show a lower sensitivity for AKI diagnosis than urinary biomarkers [59, 60]. 
NGAL is currently the most considered biomarker in AKI. However, it is non-specific to AKI 
and may be increased by activated neutrophils due to the response of systemic infection. We 
have demonstrated the  benefit of NGAL and Cys-C in SA-AKI with bilateral nephrectomy 
and bilateral ureter obstruction models [33, 61]. Cys-C is generated from all nucleated cells 
and NGAL produced from several organs (lung, heart, kidney, and spleen). Because NGAL 
is reabsorbed from proximal tubules but produced from distal renal tubules [62], NGAL is not 
only a biomarker of proximal tubular function but also a biomarker of renal injury. Although 
both molecules are not specific for kidney, NGAL and Cys-C increase more rapidly than SCr after 
bilateral nephrectomy, possibly due to the more intrinsic sources in the body than SCr. While 
SCr is generated from muscle due to the utilization of creatine, these molecules are generated 
from several organs including muscle. It is interesting to note that renal NGAL, as determined 
by Western blot analysis, after bilateral ureter obstruction, does not increase as rapidly as serum 
NGAL [33]. This implies the possible limited utilization of kidney-specific NGAL (monomeric 
form of NGAL) for SA-AKI diagnosis. It is also interesting to note that sepsis does not enhance the 
production of creatinine, NGAL and Cys-C. SCr and Cys-C after CLP in bilateral nephrectomized 
mice are lower than CLP in normal mice. And serum NGAL in bilateral nephrectomized mice is 
not different to the level of CLP in normal mice [33]. In this aspect, among these biomarkers, SCr 
has several limitations and NGAL is the best  representative for SA-AKI in these mouse models.
For other biomarkers, urine IL-18 is a cytokine that respond not only to AKI but also to 
 inflammation and infection. Urine L-FABP has been reported as a good predictor of  mortality 
in patients with sepsis in ICU and shows the significant higher level in SA-AKI in  comparison 
with sepsis-non-AKI [63]. In addition, urine exosome is another interesting source of  candidate 
AKI biomarkers. Exosome is the nanosize vesicle containing molecules from  cytoplasm 
or nuclei surrounded by some parts of cell membrane [62, 64–66]. Exosome is another 
 mechanism of cell-cell communication possibly aiming to deliver non-soluble molecules 
and/or ligands of cell membrane receptor. As such, MHC-containing exosome could activate 
other immune cells in a distance without the necessary for the close proximity activation [64]. 
Moreover, several rapid-degradable molecules (RNA, miRNAs) or molecules of intra-nuclei 
(e.g., transcriptional factors) could be protected and delivered by exosome. Likewise, our 
group recently demonstrates the role of urine exosomal ATF-3 as a good additional biomarker 
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for determining the onset of AKI in sepsis [62]. The summary of promising urine and serum 
biomarkers for SA-SKI is shown in Table 1. Although only a single biomarker might be 
already useful for SA-AKI determination, the combination would be even more beneficial in 
the clinical practice. For examples, an increase in biomarkers of injury but not biomarkers of 
renal function could represent subclinical AKI (normal SCr). And an increase in functional 
biomarkers but not biomarkers of cell injury may represent CKD. More studies are needed.
The discovery of early biomarker of SA-AKI not only improves the clinical management 
strategies but also adds up the understanding in the pathophysiology of SA-AKI. Unfortunately, 
SA-AKI pathophysiology in patients is not straightforward. Several  comorbidities and the 
exposure to other AKI inducers (radiologic contrast-media (contrast-induced nephropathy), 
antibiotics (nephrotoxic ATN or acute interstitial nephritis), and hypotensive state (ischemic 
ATN) enhance the complexity of sepsis in patients. Hence, the major molecules  responsible 
for SA-AKI in each patient might be different and the different approach and therapies 
might be necessary. For an example, SA-AKI with the predominant of HMGB1 versus high 
 activated protein C might require the different managements. Therefore, it might be difficult 
to  recognize the molecular responses of SA-AKI only by patient history or current  biomarkers. 
More serum, urine, or tissue biomarkers should be beneficial. Thus, appropriate techniques of 
renal biopsy in an appropriate time point of SA-AKI might be helpful for an early diagnosis 
and exploration of the individual molecular responses. This approach could be one of the 
strategies for “sepsis-individualized therapy.” As such, numerous renal biopsy techniques 
have high yields, safe and effortless [67, 68]. The studies of renal biopsy in the selected case of 
patients with AKI will be very interesting.
In addition, the interpretation of some non-renal biomarkers in AKI should be cautious. For 
examples, cardiac troponin I, a biomarker of cardiac muscle injury, is usually high in patients 
with abnormal renal function [69]. Troponin I of >0.8 ng/dL or the alterations from baseline 
level or additional use of other biomarkers (e.g., myocardial creatinine kinase; CKMB) might 
be helpful to determine cardiac cell injury. Fluid status in SA-AKI could affect N-terminal 
pro-B-type natriuretic peptide (NT-BNP) and troponin T [70]. We also explore microRNA-122 
(miR122), a new liver injury biomarker, in several mouse models including sepsis [71]. We 
found that miR-122 is not superior than alanine transaminase (ALT) for the detection of 
 sepsis-induced liver injury.
Indices Timing of 
measurement
AUROC Threshold 
values
Sensitivity Specificity References (year)
Urine biomarker(s)
NGALa (ng/mg 
creatinine)
12-h following 
septic shock
0.86 >68 0.71 1.0 Martensson et al. [72] 
(2010)
sTREM-1a (pg/mL) 48-h before AKI 
diagnosis*
0.92 69.04 0.94 0.76 Su et al. [73] (2011)
Cys-Ca (mg/L) Within 8 days after 
admission
0.86 0.106 0.85 0.80 Aydoğdu et al. [60] 
(2013)
NGALa (ng/mL) 0.80 29.5 0.88 0.73
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Indices Timing of 
measurement
AUROC Threshold 
values
Sensitivity Specificity References (year)
NGALa (ng/mL) 7 days after onset 
of sepsis
0.86 402 0.89 0.74 Fan et al. [74]
NGALa (ng/mL) 24 h after 
admission
0.78 350 0.75 0.82 Matsa et al. [75] (2014)
α1ma (mg/L) 24 h before AKI 
onset
0.74 47.9 0.88 0.62 Terzi et al. [76] (2014)
Cys-Ca (mg/L) 24 h before AKI 
onset
0.74 N/A N/A N/A Dai et al. [77] (2015)
NGALa (ng/mL) 0.88 N/A N/A N/A
sTREM-1a (pg/mL) 0.78 N/A N/A N/A
ATF3b (ng/mL) 24 h before AKI 
onset
0.84 12 0.93 0.85 Panich et al. [62] (2017)
NGALb (ng/mL) 0.64 150 0.98 0.44
Serum or plasma biomarker(s)
NGAL (ng/mL) 12 h following 
septic shock
0.67 >120 0.83 0.50 Martensson et al. [72] 
(2010)
Cys-C (mg/L) Within 8 days of 
admission
0.82 1.5 0.73 0.68 Aydoğdu et al. [60]
(2013)
NGAL (ng/mL) 0.44 N/A N/A N/A
NGAL (ng/mL) 24 h after 
admission
0.88 400 0.79 0.75 Matsa et al [75](2014)
Presepsin (pg/mL) Within 24 h of 
admission
0.70 670 0.70 0.81 Nakamura et al. [78]
Procalcitonin (ng/
mL)
Within 24 h of 
admission
0.88 0.42 0.95 0.65 Nakamura et al. [79]
(2015)
Cys-C (mg/L) 24 h before AKI 
onset
0.74 N/A N/A N/A Dai et al. [77] (2015)
NGAL (ng/mL) 0.83 N/A N/A N/A
sTREM-1 (pg/mL) 0.75 N/A N/A N/A
α1m, alpha-1-microglobulin; AKI, acute kidney injury; ATF3, activating transcriptional factor 3; AUROC, area under 
the receiver operating characteristic curve; Cys-C, cystatin-C; N/A, data not available; NGAL, neutrophil gelatinase-
associated lipocalin; sTREM-1, soluble-triggering receptor expressed on myeloid cells-1.
*No data were available 24 h before AKI onset.
aDetection from urinary soluble fraction part.
bDetection from urinary exosomal part.
Table 1. Summary of the published studies in early urine and plasma biomarkers for detecting SA-AKI.
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7. Managements
Similar to general managements in sepsis, SA-AKI treatment bases upon the rapidly 
 appropriate antibiotic administration and best supportive cares. Here, we summarized the 
important points in SA-AKI management.
7.1. Fluid therapy
Fluid administration is the corner stone of resuscitation especially in sepsis. Theoretically, 
fluid responder defines by a patient whose stroke volume (SV) increases by 10–15% after a 
fluid challenge (250–500 mL) [80], but less than 40% of septic patients are fluid responders 
[81]. According to Frank-Starling principle, as the preload increases, SV increases until the 
optimal preload is achieved. Thus, if the fluid challenge does not increase SV, the amount of 
volume loading would be harmful from the increase in arterial pressure, venous pressure, 
and, in the end, pulmonary hydrostatic pressures. Moreover, these responses stimulate the 
release of natriuretic peptide that induces fluid shift from intravascular portion into interstitial 
space. Of note, kidney is also particularly affected by increased venous pressure resulting in 
increased renal subcapsular pressure and decreased GFR.
“Fluid expansion as supportive therapy” (FEAST) is the most explicit study that  demonstrates 
the harmful of fluid loading in sepsis [82]. In this randomized study, aggressive fluid 
loading is associated with an increased risk of death. After the concept of early aggressive 
fluid resuscitation—“early goal directed therapy” (EGDT)—published in 2001 [83], a  number 
of studies using EGDT protocol have been published subsequently [84–86]. Interestingly, 
these studies show an obvious reduction in mortality rate, especially during 2010–2015, which 
associates with the decline in the volume of fluid resuscitation in the first 72 h. Although 
the fluid resuscitation in an early phase of sepsis with a significant decrease in effective 
circulatory volume sounds reasonable, the ongoing fluid maintenance therapy remains in 
trouble, particularly in SA-AKI [87]. Fluid therapy, moreover, is not only incapable of  effective 
reverse septic shock but also contribute to the more renal dysfunction through  several 
 mechanisms. For instance, an increased venous pressure following fluid therapy directly 
increases pressure in renal interstitium and peritubular area in animal models [88]. Because 
a large fluid bolus (20–30 mL/kg) is associated with volume overload, the approach with the 
less volume of fluid bolus (200–500 mL) is currently recommended [89]. Acute dialysis quality 
initiative (ADQI) suggests the approach of fluid therapy in sepsis by dividing into four stages: 
rescue, optimization, stabilization, and de-escalation [5]. High-volume resuscitation is needed 
during the rescue stage followed by optimization and stabilization protocol depending on the 
individual patient. After that, the de-escalation consists of reduced total fluid water in patients 
where diuretics and/or renal replacement therapy (RRT) might be necessary. Regarding fluid 
therapy monitoring, passive leg-raising maneuver (PLR) after fluid bolus combined with the 
real-time SV measurement is the only procedure with a high clinical accuracy of fluid status 
[80, 89]. Due to the availability of ultrasonography in most of the ICUs, the exclusion of fluid 
overload by the real-time detection of B-line and abnormal curtain sign in the lung, the vena cava 
collapsibility by M-mode ultrasonography, and the abnormalities in cardiac function is noninvasive 
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and might be helpful as the additional information in the real clinical situation. But these 
procedures are operator dependent that need a special training. Nevertheless, physical 
 examination, central venous pressure (CVP), central venous oxygen saturation (ScvO
2
), chest 
radiography, and the vena-caval collapsibility index by ultrasonography show limited value 
in fluid monitoring and is not generally recommended for fluid challenge purpose [90–92]. It 
might be important to note that in patients with previous normal blood pressure, the mean 
arterial pressure (MAP) at 65–70 mmHg might be adequate for maintaining renal perfusion. 
But MAP at 80–85 mmHg might be needed in patient with a history of hypertension [93]. 
Moreover, serum lactate should be less than 2 mmol/L. The new definition of septic shock 
from the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), the 
stage with the need of vasopressor from maintaining MAP ≥65 mmHg and serum lactate more 
than 2 mmol/L, implies the importance of serum lactate and vasopressor in clinical practice [1].
In addition to the amount of volume, fluid composition is another issue that must be considered 
in SA-AKI. Normal saline (0.9% NaCl), a non-physiologic solution, is possibly less beneficial in 
SA-AKI than other new fluid preparations. Normal saline causes a hyperchloremic metabolic 
acidosis resulting in decreased renal blood flow (by activation of TG feedback mechanisms 
and afferent vasoconstriction) and increases the risk of further renal injury [94, 95]. Moreover, 
normal saline is associated with an increased risk of death in comparison with physiologic 
salts solution. Similarly, synthetic hydroxyethyl starch is potentially nephrotoxic and not 
recommended in SA-AKI patients [96]. Blood transfusion is used to improve  microcirculatory 
hemoglobin and tissue oxygenation. However, the results of blood transfusion in reducing 
morbidity and mortality remain inconclusive [96, 97]. Despite theoretical disadvantage of 
normal saline in SA-AKI, the result from randomized control trial is still controversy. 
Moreover, normal saline is generally available in a reasonable price worldwide. Thus,  normal 
saline should still be a main fluid replacement used in SA-AKI. However, the alternative 
 administration of normal saline with other fluid preparations or the limited volume of normal 
saline might be more beneficial. Recently, Steward approach on acid-base proposed the ratio of 
serum chloride/sodium (S
Cl
/S
Na
) at higher than 0.76 as the indication of chloride access and the 
timing for the replacement of normal saline into other solutions [98]. More studies are needed.
7.2. Control of acidosis
Acidosis is common in patients with sepsis which might be due to lactic acidosis, respiratory 
acidosis, and/or hyperchloremic metabolic acidosis from high volume of  normal saline. 
But bicarbonate treatment is not recommended unless blood pH is lower than 7.15. 
Sodium  bicarbonate infusion leads to hypernatremia, hypervolemia, intracellular shift of 
 calcium-induced  hypocalcemia, intracellular acidosis, and impaired oxygen delivery [99]. 
Improved tissue perfusion, proper respiratory machine adjustment, and balance  administration 
of  high-volume normal saline with other fluid therapy (e.g., other balance solutions) should be 
helpful.  Tris-hydroxy methyl amino methane (THAM), a weak base with intracellular  diffusion, 
might be beneficial due to the lower intracellular acidosis in  comparison with  bicarbonate 
infusion. However, THAM causes hyperkalemia, hypoglycemia,  pseudohyponatremia, and 
increased osmolol gap in patients with preexisting renal dysfunction due to the excretion 
through  kidney [100].
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7.3. Antibiotics and other nephrotoxic
The rapid control organism is still the main theme of sepsis treatment. The survival rate of 
patients with sepsis declines 7.6% for every hour of delayed appropriate antibiotic  treatment 
[101]. Regarding AKI from antibiotic, vancomycin is reported to induce AKI despite 
 appropriate therapeutic level (15–20 mg/dL; the recommended level for the treatment 
of  methicillin-resistance Staphylococcus aureus (MRSA)). Vancomycin is also reported to enhance 
nephrotoxic of piperacillin-tazobactam [102]. Although these events might be due to the 
 contaminants, vancomycin administration in a high dose should be careful and blood level 
monitoring might be helpful. Other unnecessary nephrotoxic substances, such as  amphotericin 
B, iodinated contrast agents, and so on, should be avoided. In addition, there is only a report 
of gadolinium (a contrast for MRI)-induced AKI [103] but several reports on increase  incidence of 
nephrogenic systemic fibrosis in gadolinium injection in patients with preexisting renal injury.
7.4. Vasopressors
In SA-AKI, the alteration of vascular tone is a major cause of hypotension and renal injury. 
Norepinephrine maintains mean arterial pressure and increases renal medullary circulation 
without RBF alteration leading to improved renal function both in animal models and in human 
[93, 104–106]. Norepinephrine also restores normal capillary velocity and filtration pressure 
[107]. Thus, norepinephrine is the first-line drug for septic shock. On the other hand, iloprost, a 
vasodilatory prostacyclin, has been considered to reduce cortical microcirculatory hypoxia and 
preserve renal function in animal model of SA-AKI [108]. But the clinical data on the efficacy 
and safety of iloprost administration are still limited.
7.5. Renal replacement therapy
The general four concerning aspects of renal replacement therapy (indications, timing, 
modality, and delivered dose) and the traditional clinical indications of RRT (“A-E-I-O-U”; 
A-acidosis, E-electrolyte disturbance, I-intoxication, O-fluid overload, and U-uremia) should 
be applied to SA-AKI as other causes of AKI. Indeed, severe metabolic acidosis, fluid  overload, 
and uremia are the top three common indications for RRT in SA-AKI.
Regarding the timing of RRT initiation, the data are heterogeneous, inconclusive, and  centers 
dependence. Although adverse effect of delayed RRT initiation has been reported with a 
higher mortality rate and worse renal outcome in SA-AKI [109], many consensus guidelines 
remain set as individual timing based on the only published randomized controlled trial. 
Bouman et al. [110] demonstrated non-significant differences in renal outcomes or patient 
survival between early and late initiation of hemofiltration. As such, the recently two large, 
high-profile randomized trials, specifically designed for the determination of RRT initiation 
in patients with AKI and critically ill condition, show the discordant conclusions [111, 112]. 
Single-center early versus late initiation of renal replacement therapy on mortality in critically 
ill patients with acute kidney injury (ELAIN) demonstrates the benefit of an early strategy of 
RRT initiation over a delay strategy in the mortality rate of critically ill patients [113]. Although 
eligible patients are at KDIGO stage 2, they have high sequential organ failure assessment 
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(SOFA) score at 15.6–16.0. On the contrary, the artificial kidney initiation in kidney injury 
(AKIKI) study shows a negative result for early strategy of RRT initiation [114]. But patients 
enrolled in the AKIKI trial are at KDIGO stage 3 with SOFA score at 10.8–10.9 which is lower 
than the patients in ELAIN study. In addition, SOFA score in the renal component in AKIKI 
trial is also less than ELAIN study. Therefore, these two studies may have come to different 
conclusions because of the different inclusion criteria. The patients enrolled in the ELAIN trial 
are at an earlier AKI stage but more severe sepsis. Nevertheless, another trial for answering 
the optimal RRT timing is now ongoing—STARRT-AKI (standard vs. accelerated initiation of 
renal replacement therapy in acute kidney injury) study; clinicaltrial.gov NCT02568722.
The choice of hemodialysis (HD) modality for patients with SA-AKI is also important to 
 mention. Although the best choice of HD modality in SA-AKI remains inconclusive, only some 
studies showed the benefit of continuous renal replacement therapy (CRRT) over  intermittent 
hemodialysis (IHD) in survival and duration before renal recovery [115, 116]. Regarding CRRT 
in SA-AKI setting, continuous venovenous hemofiltration (CVVH) has recently  demonstrated 
the promising results in comparison with extended daily  hemofiltration (EDHF) [115]. Despite 
more severe sepsis (oliguria and severity of metabolic acidosis) of patients in CVVH group, 
they have a superior renal outcome on 60-day dialysis independence periods. However, a 
retrospective cohort study by AlEnezi et al. showed that CVVH does not attenuate  mortality 
and length of hospital stay in comparison with continuous venovenous hemodiafiltration 
(CVVHDF) [116].
Although the benefit of renal recovery is superior in CRRT, over IHD, owing to the better fluid 
control with the fewer hypotensive episodes, CRRT is more expensive. On the other hand, on-line 
hemodiafiltration (Ol-HDF), an intermittent hemodialysis modality that increase  mid-to-large 
molecular clearance by combining diffuse and convective transport with  ultrapure dialysate, is a 
promising alternative modality for SA-AKI. Data from our study demonstrated that Ol-HDF not 
only benefits in renal support but also offers a potential role in immune modulation in SA-AKI 
[117]. The comparison of beneficial effects on renal outcomes and patient survival between 
CVVH and Ol-HDF in SA-AKI patients is ongoing in our center.
In addition, optimal CRRT dose is evaluated in two clinical trials with nonspecific causes of 
AKI at an effluent rate of 25–30 and 40 mL/kg/h [118–120]. Although there is a tendency toward 
the reduced mortality rate in the higher dose of CRRT (40 mL/kg/h), it is not enough to reach 
a significant level. Likewise, the CRRT prescription dose at 30–35 mL/kg/h or 25%  addition 
to the usual dose of CRRT is recommended by some centers to ensure an adequate  delivered 
dose [121]. By theory, delivered CRRT dose over 35 mL/kg/h as known as  “high-volume 
hemofiltration” may remove systemic inflammation and improve septic shock survival, but it 
is not supported by several clinical studies.
It seems that CVVH has more benefit than IHD only in limited parameters with a significantly 
higher cost. Hence, we recommend IHD or sustained/slow low-efficiency dialysis (SLED) 
as a first choice of RRT modality followed by standard dose of CVVH (20–25 mL/kg/h) in 
SA-AKI depending on patient conditions. In addition, in the area with the limited resources, 
with less severe sepsis, and/or without other choices of RRT, peritoneal dialysis (PD) might 
be an  alternative RRT modality [122]. However, the adequacy of PD in sepsis and the high 
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 glucose level in peritoneal dialysate is the major limitation of PD in sepsis. On the other hand, 
extracorporeal blood purification (EBP) is currently considered as one of the treatments for 
 balancing homeostasis of sepsis immune responses. The absorption therapy with polymyxin B 
or other cytokine absorbents shows benefit in hemodynamic parameters and mortality rate in 
some studies [123] but still inconclusive. Therefore, the specific indication and/or proper bio-
markers (i.e., stress-, injury-, functional loss-, and recovery biomarkers) to select patients with 
the highest probability to be beneficial from any treatment methods are urgently in need [124].
8. Conclusions
Sepsis is often accompanied by acute renal failure, also called sepsis-associated acute kidney 
injury. The mechanisms by which sepsis and endotoxemia lead to SA-AKI are incompletely 
understood. However, growing evidences suggest that SA-AKI is a result of sustained renal 
microvascular hypoperfusion, insufficient cell energy, mitochondria dysfunction, endothelial 
injury, and cell cycle arrest. SA-AKI is associated with normal or even elevated renal blood 
flow, which is, at least in part, due to redistribution of blood flow from cortical to  medullary 
region. Fluid therapy and proper antibiotics are crucial managements. Because too much 
fluid administration in sepsis increase organ dysfunction, hemodynamic-guided approach of 
fluid therapy and early vasopressor administration in SA-AKI would be beneficial. Currently, 
the role of renal replacement (RRT) in SA-AKI for renal support and immunomodulation 
has been evaluated. Although there is no consensus guideline, retrospective clinical  studies 
have suggested that the early initiation of RRT and the use of continuous methods are 
associated with a better hemodynamic tolerance and renal outcome. Timing and dose of RRT 
are  ongoing debate, yet recently randomized clinical trials remain unable to demonstrate any 
beneficial impacts of early RRT. In the future, we propose “sepsis mechanistic approach” as 
an individualized therapy for sepsis and the better matching between the results from the 
translational researches and the specific patient characteristics.
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